• Profile
Close

Lymphoma drug outperforms Remdesivir against COVID virus

IANS Jan 04, 2021

A chemotherapy medication originally developed to treat lymphoma has outperformed the popular remdesivir drug against SARS-CoV-2 in lab settings, and could potentially be repurposed to treat COVID-19, say researchers.

For our comprehensive coverage and latest updates on COVID-19 click here.


A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate drug is a promising candidate for COVID-19 patients. The novel screening approach identified four promising drugs, which were then tested against SARS-CoV-2 in lab experiments. Two of the drugs, pralatrexate and azithromycin, successfully inhibited replication of the virus.

Further lab experiments showed that pralatrexate more strongly inhibited viral replication than did remdesivir, a drug that is currently used to treat some COVID-19 patients, said Haiping Zhang of the Shenzhen Institutes of Advanced Technology in Shenzhen, China. Zhanh and team screened 1,906 existing drugs for their potential ability to inhibit replication of SARS-CoV-2 by targeting a viral protein called RNA-dependent RNA polymerase (RdRP).

The findings, published in open-access journal PLOS Computational Biology, suggest that pralatrexate could potentially be repurposed to treat COVID-19. "However, this chemotherapy drug can prompt significant side effects and is used for people with terminal lymphoma, so immediate use for COVID-19 patients is not guaranteed. Still, the findings support the use of the new screening strategy to identify drugs that could be repurposed," the researchers noted.

With the COVID-19 pandemic causing illness and death worldwide, better treatments are urgently needed. One shortcut could be to repurpose existing drugs that were originally developed to treat other conditions. "We have demonstrated the value of our novel hybrid approach that combines deep-learning technologies with more traditional simulations of molecular dynamics," Zhang said. He and his colleagues are now developing additional computational methods for generating novel molecular structures that could be developed into new drugs to treat COVID-19.

Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay